Lead optimisation
Hit to lead
Assay Development
Therapeutic area
  • Cardiovascular disease; osteolytic diseases /oncology

Project Aim

First-in-class anti-netrin-1 humanised antibody for the treatment of atherosclerosis


An anti-netrin-1 therapeutic offers the potential to reverse atherosclerosis with an additive benefit to cholesterol reduction interventions

Target Class

Dependence Receptor Ligand



Current Status

Hit to Lead. Antibody characterisation and selection prior to humanisation

Intellectual Property

Initial filings with the opportunity to create a protective IPR portfolio


Licence or shared risk collaboration

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities